BioSpace News Archive

The Company will host a conference call to discuss the financial results and other business developments.

The suit was triggered by notifications received from Mylan beginning in mid-September

OptiBiotix, a world leader in the modulation of the human microbiome, has signed a supply agreement for its cholesterol and blood pressure-reducing probiotic, LPLDL, with the food division of Galenicum Health, a leading Spanish pharmaceutical group.

Ironshore Pharmaceuticals & Development, Inc. announced the presentation of new analyses of pivotal trial data for evening-dosed HLD200, also known as DR/ER-MPH (delayed-release and extended-release methylphenidate) at the American Academy of Child and Adolescent Psychiatry (AACAP) annual meeting.

The Clarisolve mPAA polymer is a stimulus-responsive flocculation polymer designed specifically to enable a simpler clarification of high density cell culture monoclonal antibody (mAb) processes, and provides an alternative to centrifugation for these challenging bioreactor harvests when used in combination with Clarisolve® depth filters.

Neurocrine announced today that it has initiated a Phase IIb clinical trial, T-Force GOLD, for INGREZZAr, in children and adolescents with Tourette syndrome.

Vermillion announced today that it will report its third quarter 2017 financial results on Wednesday, November 8, 2017, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Varian today announced it has been selected to install a ProBeam four-room proton therapy system in the new Guangzhou Concord Cancer Hospital.

Cardiovascular Systems, Inc.: Conference Call Scheduled for Today, October 25, 2017, at 3:45 PM CT (4:45 PM ET).

C. R. Bard, Inc. today reported 2017 third quarter financial results.